Charles River (CRL) and Gazi University Faculty of Medicine announced a gene therapy contract development and manufacturing organization collaboration, providing plasmid DNA for AAV production and in vitro efficacy studies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River price target raised to $265 from $200 at Citi
- Charles River price target raised to $231 from $224 at Baird
- Charles River Labs outlines 2026 outlook and acquisitions
- Charles River price target raised to $260 from $250 at Evercore ISI
- Charles River to buy KF Cambodia for $510M, exercises option for Pathoquest